Mitomycin Substipharm (Mitomycin)

Mitomycin works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This interference leads to cell cycle arrest and triggers apoptosis in rapidly dividing cancer cells.

The dose of Mitomycin Substipharm is determined by the prescribing physician based on the specific indication, patient weight, renal function, and treatment protocol. Dosage regimens are individualized and should follow the clinician’s orders.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Use only if the potential benefits outweigh the risks and under strict medical supervision.

To order Mitomycin Substipharm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mitomycin belongs to the alkylating antibiotic class and differs from agents such as cisplatin or carboplatin by its DNA‑cross‑linking mechanism and intravesical formulation for bladder cancer. Its toxicity profile includes notable myelosuppression and renal effects, which may be more pronounced than some platinum‑based drugs.

Mitomycin Substipharm should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability.

Mitomycin Substipharm is administered either intravenously for systemic cancer treatment or intravesically for bladder cancer. Intravenous infusion is performed by a qualified healthcare professional, while intravesical administration involves instilling the solution directly into the bladder.

The most serious risks include severe bone marrow suppression leading to pancytopenia, pulmonary toxicity such as interstitial pneumonitis, and renal toxicity that can progress to acute kidney injury. Prompt monitoring of blood counts, lung function, and renal parameters is essential.

Mitomycin Substipharm should not be used in patients with known hypersensitivity to mitomycin or related compounds, in those with severe renal impairment, or in pregnant women unless absolutely necessary. Caution is also advised for patients receiving concurrent radiation therapy.